Novel curcumin oral delivery systems

Anticancer Research

Volumn 33, Issue 7, 2013, Pages 2807-2822

  Kurita, Takuro ^a   Makino, Yuji ^a,b  

^a TOKUSHIMA BUNRI UNIVERSITY   (Japan)

^b TOKYO UNIVERSITY OF SCIENCE   (Japan)

Author keywords

Bioavailability; Curcumin; Drug delivery system; Oral absorption; Review

Indexed keywords

ALCOHOL DEHYDROGENASE; BIOCURCUMAX; CELL ADHESION MOLECULE; CELL CYCLE PROTEIN; CURCUMIN; CYCLODEXTRIN; EARLY GROWTH RESPONSE FACTOR 1; EPIDERMAL GROWTH FACTOR RECEPTOR; GAMMA UROGASTRONE; GROWTH FACTOR; GROWTH FACTOR RECEPTOR; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; LIPOXYGENASE; LONGVIDA; MATRIX METALLOPROTEINASE; MERIVA; PHOSPHATIDYLCHOLINE; PIPERINE; PLASMINOGEN ACTIVATOR; PROTEIN TYROSINE KINASE; SOMATOMEDIN; STRESS ACTIVATED PROTEIN KINASE; THERACURMIN; TRANSCRIPTION FACTOR; TRANSCRIPTION FACTOR AP 1; TUMOR NECROSIS FACTOR; TURMERIC; UNCLASSIFIED DRUG;

ALZHEIMER DISEASE; ANGIOGENESIS; ANTINEOPLASTIC ACTIVITY; AREA UNDER THE CURVE; CANCER CELL CULTURE; CELL GROWTH; CELL INVASION; CELL PROLIFERATION; COLORECTAL CANCER; COMPLEX FORMATION; CONFERENCE PAPER; DEPRESSION; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG DELIVERY SYSTEM; DRUG DOSAGE FORM; DRUG FORMULATION; DRUG GLUCURONIDATION; DRUG METABOLISM; DRUG PENETRATION; DRUG SAFETY; DRUG SENSITIVITY; DRUG SOLUBILITY; HUMAN; IN VITRO STUDY; IN VIVO STUDY; INTRACELLULAR SIGNALING; MAXIMUM PLASMA CONCENTRATION; METASTASIS; MICELLE; MULTIPLE MYELOMA; NONHUMAN; PHYSICAL CHEMISTRY; PRIORITY JOURNAL; PROSTATIC INTRAEPITHELIAL NEOPLASIA; THERAPY EFFECT; TIME TO MAXIMUM PLASMA CONCENTRATION;

BIOAVAILABILITY; CURCUMIN; DRUG DELIVERY SYSTEM; ORAL ABSORPTION; REVIEW;

ADMINISTRATION, ORAL; ANIMALS; CURCUMIN; DRUG DELIVERY SYSTEMS; HUMANS; NEOPLASMS;

EID: 84883309280     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (72)

1. Li W, Wang S, Feng J, Xiao Y, Xue X, Zhang H, Wang Y and Liang X: Structure elucidation and NMR assignments for curcuminoids from the rhizomes of Curcuma longa. Magn Reson Chem 47(10): 902-908, 2009.
2. Nishiyama T, Mae T, Kishida H, Tsukagawa M, Mimaki Y, Kuroda M, Sashida Y, Takahashi K, Kawada T, Nakagawa K and Kitahara M: Curcuminoids and sesquiterpenoids in turmeric (Curcuma longa L.) suppress an increase in blood glucose level in type 2 diabetic KK-Ay mice. J Agric Food Chem 53(4): 959-963, 2005.
3. Goel A, Kunnumakkara AB and Aggarwal BB: Curcumin as " Curecumin": from kitchen to clinic. Biochem Pharmacol 75(4): 787-809, 2008.
4. Zhou H, Beevers CS and Huang S: The targets of curcumin. Curr Drug Targets 12(3): 332-347, 2011.
5. Shishodia S: Molecular mechanisms of curcumin action: Gene expression. Biofactors 39(1): 37-55, 2013.
6. Gupta SC, Patchva S and Aggarwal BB: Therapeutic roles of curcumin: Lessons learned from clinical trials. AAPS J 15(1): 195-218, 2013.
7. Aggarwal BB, Kumar A and Bharti AC: Anticancer potential of curcumin: Preclinical and clinical studies. Anticancer Res 23(1A): 363-398, 2003.
8. Bharti AC, Donato N, Singh S and Aggarwal BB: Curcumin (diferuloylmethane) down-regulates the constitutive activation of nuclear factor-kappa B and IkappaBalpha kinase in human multiple myeloma cells, leading to suppression of proliferation and induction of apoptosis. Blood 101(3): 1053-1062, 2003.
9. Su CC, Chen GW, Lin JG, Wu LT and Chung JG: Curcumin inhibits cell migration of human colon cancer Colo-205 cells through the inhibition of nuclear factor kappa B/p65 and downregulates cyclooxygenase-2 and matrix metalloproteinase-2 expressions. Anticancer Res 26(2A): 1281-1288, 2006.
10. Patel BB, Gupta D, Elliott AA, Sengupta V, Yu Y and Majumdar AP: Curcumin targets FOLFOX-surviving colon cancer cells via inhibition of EGFRs and IGF-1R. Anticancer Res 30(2): 319-325, 2010.
11. Esatbeyoglu T, Huebbe P, Ernst IM, Chin D, Wagner AE and Rimbach G: Curcumin-from molecule to biological function. Angew Chem Int Ed Engl 51(22): 5308-5332, 2012.
12. Dhillon N, Aggarwal BB, Newman RA, Wolff RA, Kunnumakkara AB, Abbruzzese JL, Ng CS, Badmaev V and Kurzrock R: Phase II trial of curcumin in patients with advanced pancreatic cancer. Clin Cancer Res 14: 4491-4499, 2008.
13. Capodice JL, Gorroochurn P, Cammack AS, Eric G, McKiernan JM, Benson MC, Stone BA and Katz AE: Zyflamend in men with high-grade prostatic intraepithelial neoplasia: Results of a phase I clinical trial. J Soc Integr Oncol 7(2): 43-51, 2009.
14. Golombick T, Diamond TH, Manoharan A and Ramakrishna R: Monoclonal gammopathy of undetermined significance, smoldering multiple myeloma, and curcumin: A randomized, double-blind placebo-controlled cross-over 4 g study and an openlabel 8 g extension study. Am J Hematol 87(5): 455-460, 2012.
15. Yan YD, Kim JA, Kwak MK, Yoo BK, Yong CS and Choi HG: Enhanced oral bioavailability of curcumin via a solid lipid-based self-emulsifying drug delivery system using a spray-drying technique. Biol Pharm Bull 34(8): 1179-1186, 2011.
16. Hu L, Jia Y, Niu F, Jia Z, Yang X and Jiao K: Preparation and enhancement of oral bioavailability of curcumin using microemulsions vehicle. J Agric Food Chem 60(29): 7137-7141, 2012.
17. Griesser M, Pistis V, Suzuki T, Tejera N, Pratt DA and Schneider C: Autoxidative and cyclooxygenase-2 catalyzed transformation of the dietary chemopreventive agent curcumin. J Biol Chem 286(2): 1114-1124, 2011.
18. Dempe JS, Scheerle RK, Pfeiffer E and Metzler M: Metabolism and permeability of curcumin in cultured Caco-2 cells. Mol Nutr Food Res 29: Advance online publication. doi: 10.1002/mnfr.201200113, 2012.
19. Artursson P and Karlsson J: Correlation between oral drug absorption in humans and apparent drug permeability coefficients in human intestinal epithelial (Caco-2) cells. Biochem Biophys Res Commun 175(3): 880-885, 1991.
20. Wahlang B, Pawar YB and Bansal AK: Identification of permeability-related hurdles in oral delivery of curcumin using the Caco-2 cell model. Eur J Pharm Biopharm 77(2): 275-282, 2011.
21. Wortelboer HM, Usta M, van der Velde AE, Boersma MG, Spenkelink B, van Zanden JJ, Rietjens IM, van Bladeren PJ and Cnubben NH: Interplay between MRP inhibition and metabolism of MRP inhibitors: The case of curcumin. Chem Res Toxicol 16(12): 1642-1651, 2003.
22. Holder GM, Plummer JL and Ryan AJ: The metabolism and excretion of curcumin (1,7-bis-(4-hydroxy-3-methoxyphenyl)-1,6- heptadiene-3,5-dione) in the rat. Xenobiotica 8(12): 761-768, 1978.
23. Wahlstrom B and Blennow G: A study on the fate of curcumin in the rat. Acta Pharmacol Toxicol 43(2): 86-92, 1978.
24. Yang KY, Lin LC, Tseng TY, Wang SC and Tsai TH: Oral bioavailability of curcumin in rat and the herbal analysis from Curcuma longa by LC-MS/MS. J Chromatogr B Analyt Technol Biomed Life Sci 853(1-2): 183-189, 2007.
25. Onoue S, Takahashi H, Kawabata Y, Seto Y, Hatanaka J, Timmermann B and Yamada S: Formulation design and photochemical studies on nanocrystal solid dispersion of curcumin with improved oral bioavailability. J Pharm Sci 99(4): 1871-1881, 2010.
26. Vareed SK, Kakarala M, Ruffin MT, Crowell JA, Normolle DP, Djuric Z and Brenner DE: Pharmacokinetics of curcumin conjugate metabolites in healthy human subjects. Cancer Epidemiol Biomarkers Prev 17(6): 1411-1417, 2008.
27. Cheng AL, Hsu CH, Lin JK, Hsu MM, Ho YF, Shen TS, Ko JY, Lin JT, Lin BR, Ming-Shiang W, Yu HS, Jee SH, Chen GS, Chen TM, Chen CA, Lai MK, Pu YS, Pan MH, Wang YJ, Tsai CC and Hsieh CY: Phase I clinical trial of curcumin, a chemopreventive agent, in patients with high-risk or pre-malignant lesions. Anticancer Res 21(4B): 2895-900, 2001.
28. Lao CD, Ruffin MT 4th, Normolle D, Heath DD, Murray SI, Bailey JM, Boggs ME, Crowell J, Rock CL and Brenner DE: Dose escalation of a curcuminoid formulation. BMC Complement Altern Med 10: 2006.
29. Sharma RA, Euden SA, Platton SL, Cooke DN, Shafayat A, Hewitt HR, Marczylo TH, Morgan B, Hemingway D, Plummer SM, Pirmohamed M, Gescher AJ and Steward WP: Phase I clinical trial of oral curcumin: Biomarkers of systemic activity and compliance. Clin Cancer Res 10(20): 6847-6854, 2004.
30. Carroll RE, Benya RV, Turgeon DK, Vareed S, Neuman M, Rodriguez L, Kakarala M, Carpenter PM, McLaren C, Meyskens FL Jr. and Brenner DE: Phase IIa clinical trial of curcumin for the prevention of colorectal neoplasia. Cancer Prev Res 4(3): 354-364, 2011.
31. Ringman JM, Frautschy SA, Teng E, Begum AN, Bardens J, Beigi M, Gylys KH, Badmaev V, Heath DD, Apostolova LG, Porter V, Vanek Z, Marshall GA, Hellemann G, Sugar C, Masterman DL, Montine TJ, Cummings JL and Cole GM: Oral curcumin for Alzheimer's disease: Tolerability and efficacy in a 24-week randomized, double blind, placebo-controlled study. Alzheimers Res Ther 4(5): 43, 2012.
32. Garcea G, Jones DJ, Singh R, Dennison AR, Farmer PB, Sharma RA, Steward WP, Gescher AJ and Berry DP: Detection of curcumin and its metabolites in hepatic tissue and portal blood of patients following oral administration. Br J Cancer 90(5): 1011-1015, 2004.
33. Hoehle SI, Pfeiffer E, Solyom AM and Metzler M: Metabolism of curcuminoids in tissue slices and subcellular fractions from rat liver. J Agric Food Chem 54(3): 756-764, 2006.
34. Pan MH, Huang TM and Lin JK: Biotransformation of curcumin through reduction and glucuronidation in mice. Drug Metab Dispos 27(4): 486-494, 1999.
35. Shoba G, Joy D, Joseph T, Majeed M, Rajendran R and Srinivas PS: Influence of piperine on the pharmacokinetics of curcumin in animals and human volunteers. Planta Med 64(4): 353-356, 1998.
36. Antony B, Merina B, Iyer VS, Judy N, Lennertz K and Joyal S: A pilot cross-over study to evaluate human oral bioavailability of BCM-95CG (Biocurcumax), a novel bioenhanced preparation of curcumin. Indian J Pharm Sci 70(4): 445-449, 2008.
37. Lopez-Lazaro M: Anticancer and carcinogenic properties of curcumin: Considerations for its clinical development as a cancer chemopreventive and chemotherapeutic agent. Mol Nutr Food Res 52(Suppl 1): S103-S127, 2008.
38. Ireson C, Orr S, Jones DJ, Verschoyle R, Lim CK, Luo JL, Howells L, Plummer S, Jukes R, Williams M, Steward WP and Gescher A: Characterization of metabolites of the chemopreventive agent curcumin in human and rat hepatocytes and in the rat in vivo, and evaluation of their ability to inhibit phorbol ester-induced prostaglandin E 2 production. Cancer Res 61(3): 1058-1064, 2001.
39. Sandur SK, Pandey MK, Sung B, Ahn KS, Murakami A, Sethi G, Limtrakul P, Badmaev V and Aggarwal BB: Curcumin, demethoxycurcumin, bisdemethoxycurcumin, tetrahydrocurcumin and turmerones differentially regulate anti-inflammatory and antiproliferative responses through a ROS-independent mechanism. Carcinogenesis 28(8): 1765-1773, 2007.
40. Osawa T, Sugiyama Y, Inayoshi M and Kawakishi S: Antioxidative activity of tetrahydrocurcuminoids. Biosci Biotechnol Biochem 59(9): 1609-1612, 1995.
41. Pfeiffer E, Hoehle SI, Walch SG, Riess A, Solyom AM and Metzler M: Curcuminoids form reactive glucuronides in vitro. J Agric Food Chem 55(2): 538-544, 2007.
42. Sanphui P, Goud NR, Khandavilli UB, Bhanoth S and Nangia A: New polymorphs of curcumin. Chem Commun 47(17): 5013-5015, 2011.
43. Pawar YB, Shete G, Popat D and Bansal AK: Phase behavior and oral bioavailability of amorphous curcumin. Eur J Pharm Sci 47(1): 56-64, 2012.
44. Seo SW, Han HK, Chun MK and Choi HK: Preparation and pharmacokinetic evaluation of curcumin solid dispersion using Solutol® HS15 as a carrier. Int J Pharm 424(1-2): 18-25, 2012.
45. Wan S, Sun Y, Qi X and Tan F: Improved bioavailability of poorly water-soluble drug curcumin in cellulose acetate solid dispersion. AAPS PharmSciTech 13(1): 159-166, 2012.
46. Ouyang HZ, Fang L, Zhu L, Zhang L, Ren XL, He J and Qi AD: Effect of external factors on the curcumin/2-hydroxypropyl-bcyclodextrin: In vitro and in vivo study. J Incl Phenom Macrocycl Chem 73: 423-433, 2012.
47. Wacker Chemie AG: Info sheet of CAVAMAX® W8 CURCUMIN. available at http://www.wacker.com/cms/media/documents/markets-brands/life-science/ Info-Curcumin.pdf, last accessed 2nd March, 2013.
48. Maiti K, Mukherjee K, Gantait A, Saha BP and Mukherjee PK: Curcumin-phospholipid complex: Preparation, therapeutic evaluation and pharmacokinetic study in rats. Int J Pharm 330(1-2): 155-163, 2007.
49. Gupta NK and Dixit VK: Bioavailability enhancement of curcumin by complexation with phosphatidyl choline. J Pharm Sci 100(5): 1987-1995, 2011.
50. Cuomo J, Appendino G, Dern AS, Schneider E, McKinnon TP, Brown MJ, Togni S and Dixon BM: Comparative absorption of a standardized curcuminoid mixture and its lecithin formulation. J Nat Prod 74(4): 664-669, 2011.
51. Sasaki H, Sunagawa Y, Takahashi K, Imaizumi A, Fukuda H, Hashimoto T, Wada H, Katanasaka Y, Kakeya H, Fujita M, Hasegawa K and Morimoto T: Innovative preparation of curcumin for improved oral bioavailability. Biol Pharm Bull 34(5): 660-665, 2011.
52. Makino Y, Kurita T, Imaizumi A and Hashimoto T: Novel curcumin nano-suspensions with enhanced oral bioavailability and stability. Presented to 10th France-Japan DDS Symposium, October 13, 2012 (Bordeau, France).
53. Kanai M, Imaizumi A, Otsuka Y, Sasaki H, Hashiguchi M, Tsujiko K, Matsumoto S, Ishiguro H and Chiba T: Doseescalation and pharmacokinetic study of nanoparticle curcumin, a potential anticancer agent with improved bioavailability, in healthy human volunteers. Cancer Chemother Pharmacol 69(1): 65-70, 2012.
54. Sugawara J, Akazawa N, Miyaki A, Choi Y, Tanabe Y, Imai T and Maeda S: Effect of endurance exercise training and curcumin intake on central arterial hemodynamics in postmenopausal women: Pilot study. Am J Hypertens 25(6): 651-656, 2012.
55. Shaikh J, Ankola DD, Beniwal V, Singh D and Kumar MN: Nanoparticle encapsulation improves oral bioavailability of curcumin by at least 9-fold when compared to curcumin administered with piperine as absorption enhancer. Eur J Pharm Sci 37(3-4): 223-230, 2009.
56. Xie X, Tao Q, Zou Y, Zhang F, Guo M, Wang Y, Wang H, Zhou Q and Yu S: PLGA nanoparticles improve the oral bioavailability of curcumin in rats: Characterizations and mechanisms. J Agric Food Chem 59(17): 9280-9289, 2011.
57. Tsai YM, Chang-Liao WL, Chien CF, Lin LC and Tsai TH: Effects of polymer molecular weight on relative oral bioavailability of curcumin. Int J Nanomed 7: 2957-2966, 2012.
58. Muller RH, Mader K and Gohla S: Solid lipid nanoparticles (SLN) for controlled drug delivery - a review of the state of the art. Eur J Pharm Biopharm 50(1): 161-177, 2000.
59. Kakkar V, Singh S, Singla D and Kaur IP: Exploring solid lipid nanoparticles to enhance the oral bioavailability of curcumin. Mol Nutr Food Res 55(3): 495-503, 2011.
60. Fang M, Jin Y, Bao W, Gao H, Xu M, Wang D, Wang X, Yao P and Liu L: In vitro characterization and in vivo evaluation of nanostructured lipid curcumin carriers for intragastric administration. Int J Nanomed 7: 5395-5404, 2012.
61. Gota VS, Maru GB, Soni TG, Gandhi TR, Kochar N and Agarwal MG: Safety and pharmacokinetics of a solid lipid curcumin particle formulation in osteosarcoma patients and healthy volunteers. J Agric Food Chem 58(4): 2095-2099, 2010.
62. Matabudul D, Pucaj K, Bolger G, Vcelar B, Majeed M and Helson L: Tissue distribution of (Lipocurc™) liposomal curcumin and tetrahydrocurcumin following two- and eight-hour infusions in Beagle dogs. Anticancer Res 32(10): 4359-4364, 2012.
63. Helson L, Bolger G, Majeed M, Vcelar B, Pucaj K and Matabudul D: Infusion pharmacokinetics of Lipocurc™ (liposomal curcumin) and its metabolite tetrahydrocurcumin in Beagle dogs. Anticancer Res 32(10): 4365-4370, 2012.
64. Takahashi M, Uechi S, Takara K, Asikin Y and Wada K: Evaluation of an oral carrier system in rats: Bioavailability and antioxidant properties of liposome-encapsulated curcumin. J Agric Food Chem 57(19): 9141-9146, 2009.
65. Li C, Zhang Y, Su T, Feng L, Long Y and Chen Z: Silica-coated flexible liposomes as a nanohybrid delivery system for enhanced oral bioavailability of curcumin. Int J Nanomed 7: 5995-6002, 2012.
66. Yu H and Huang Q: Improving the oral bioavailability of curcumin using novel organogel-based nanoemulsions. J Agric Food Chem 60(21): 5373-5379, 2012.
67. Zhongfa L, Chiu M, Wang J, Chen W, Yen W, Fan-Havard P, Yee LD and Chan KK: Enhancement of curcumin oral absorption and pharmacokinetics of curcuminoids and curcumin metabolites in mice. Cancer Chemother Pharmacol 69(3): 679-689, 2012.
68. Setthacheewakul S, Mahattanadul S, Phadoongsombut N, Pichayakorn W and Wiwattanapatapee R: Development and evaluation of self-microemulsifying liquid and pellet formulations of curcumin, and absorption studies in rats. Eur J Pharm Biopharm 76(3): 475-785, 2010.
69. Pawar YB, Purohit H, Valicherla GR, Munjal B, Lale SV, Patel SB and Bansal AK: Novel lipid-based oral formulation of curcumin: Development and optimization by design of experiments approach. Int J Pharm 436(1-2): 617-623, 2012.
70. Bansal SS, Goel M, Aqil F, Vadhanam MV and Gupta RC: Advanced drug delivery systems of curcumin for cancer chemoprevention. Cancer Prev Res 4(8): 1158-1171, 2011.
71. Yallapu MM, Jaggi M and Chauhan SC: Curcumin nanoformulations: A future nanomedicine for cancer. Drug Discov Today 17(1-2): 71-80, 2012.
72. Tønnesen HH: Solubility, chemical and photochemical stability of curcumin in surfactant solutions. Studies of curcumin and curcuminoids, XXVIII. Pharmazie 57(12): 820-824, 2002.